PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11240954-3	2001	OBJECTIVE: The present study focused on the effects of topical tacrolimus treatment on epidermal CD1a+/FcepsilonRI+ DC populations in lesional AD.	Tacrolimus	63-73	CD1a molecule	Homo sapiens	97-101	
11240954-8	2001	Finally, topical tacrolimus led to a progressive decrease in the IDEC population within the pool of CD1a+ epidermal DCs and also to a decrease in their CD36 expression, which is indicative of lower local inflammation.	Tacrolimus	17-27	CD1a molecule	Homo sapiens	100-104	
11240954-9	2001	CONCLUSION: Epidermal CD1a+ DCs may represent a target for topical tacrolimus in the treatment of AD.	Tacrolimus	67-77	CD1a molecule	Homo sapiens	22-26	
29520229-10	2018	Results: Topical tacrolimus significantly reversed high-dose UVB irradiation-induced epidermal LC reduction and CD1a+ cell increment in culture medium.	Tacrolimus	17-27	CD1a molecule	Homo sapiens	112-116	
12091117-11	2002	In the sequential study, 5000 ng/mL FK506 before LPS addition resulted in a significant decrease in CD1a MFI and in the percentage of cells co-expressing CD83 and CD86.	Tacrolimus	36-41	CD1a molecule	Homo sapiens	100-104	
20394493-7	2010	CD1a, CD11b and CCR7 expression were all significantly down-regulated after topical treatment with tacrolimus.	Tacrolimus	99-109	CD1a molecule	Homo sapiens	0-4